We apply our proprietary AP3 patient selection platform to develop targeted precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine. Our clinical pipeline is initially focused on an advanced asset targeting the DNA Damage Response (DDR) and cell cycle regulation with demonstrated, durable single agent clinical activity in solid tumors but where genetics-based approaches have proven insufficient for response prediction. Likewise, our preclinical  programs target critical nodes in DDR pathways where we believe genetics-based approaches are insufficient for patient responder prediction. Our OncoSignature® patient selection method will be used to aim for patient responder enrichment to increase the likelihood of  successful clinical development.

See Pipeline

Acrivon Pipeline

Acrivon’s Lead Program ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, potent selective inhibitor of the DNA Damage Response checkpoint kinases, CHK1 and CHK2. ACR-368 has demonstrated deep, durable single-agent anti-tumor clinical  activity, including complete responses, in a proportion of patients with platinum-resistant ovarian cancer* and squamous cell cancer ‡. Using OncoSignature®, we have identified endometrial and bladder cancer as two additional high unmet need solid tumor types predicted to be highly sensitive to the drug candidate. Our two preclinical lead series target critical nodes in the DNA Damage Response and cell cycle pathways.

*Ref: Lee et al, Lancet Oncology (2018); ‡ Ref: Hong et al, CCR (2018)

Phase 1
Phase 2
Phase 3

ACR-368 (CHK1/CHK2)

Single-Arm Trials Based on OncoSignature Prediction
Platinum-Resistant Ovarian Cancer
Endometrial Cancer
Bladder Cancer
Staggered Development Under Same Master Protocol Trial Design
HPV+ SCC (anal, H&N and cervical cancer)

WEE1 Inhibitor

PKMYT1 Inhibitor

ACR-368 Monotherapy Registrational intent Phase 2 single arm trials based on predicted sensitivity to ACR-368 monotherapy in OncoSignature-positive patients
LDG Combination Exploratory Phase 1b/2 single arm trials of ACR-368 in combination with low dose gemcitabine, or LDG, in OncoSignature-negative patients